Announced details
SVR25: 73% at week 12 and 100% at week 24 (n=5)
TSS50: 53% at week 12 and 60% at week 24 (n=5)
Anemia response: 50%
Triple response at week 24: 60%
DLT: 0 patients
E368K mutation: 53% of patients with relapsed disease
As of 6 December 2025, 26 patients had been enrolled in the trial of the nuvisertib and momelotinib combination therapy. Of these, 15 patients were evaluable for efficacy and had completed at least 12 weeks of treatment.
Sumitomo Pharma America, Inc., the US subsidiary of Sumitomo Pharma, presented research data at the congress.
European Hematology Association. Other information, including its location, representative, capital, and year of establishment, was not disclosed.
Stockholm, Sweden (venue of EHA 2026)
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
2026 Annual Congress of the European Hematology Association (EHA)
| Item | Details |
|---|---|
| Names of Products / Services Covered | nuvisertib, enzomenib, nuvisertib and momelotinib combination therapy |
| Counterparty | European Hematology Association (EHA) |
| Counterparty overview | European Hematology Association. Other information, including its location, representative, capital, and year of establishment, was not disclosed. |
| Relationship with the Company | Sumitomo Pharma America, Inc., the US subsidiary of Sumitomo Pharma, presented research data at the congress. |
| Applicable area | Relapsed or refractory myelofibrosis, Acute leukemia, Acute myeloid leukemia |
| Location | Stockholm, Sweden (venue of EHA 2026) |
| Quantitative Effects | SVR25: 73% at week 12 and 100% at week 24 (n=5), TSS50: 53% at week 12 and 60% at week 24 (n=5), Anemia response: 50%, Triple response at week 24: 60%, DLT: 0 patients, E368K mutation: 53% of patients with relapsed disease |
| Usage history | As of 6 December 2025, 26 patients had been enrolled in the trial of the nuvisertib and momelotinib combination therapy. Of these, 15 patients were evaluable for efficacy and had completed at least 12 weeks of treatment. |
| Source | 2026 Annual Congress of the European Hematology Association (EHA) |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The presentations were made at the 2026 European Hematology Association Congress. For nuvisertib, the stated rationale was the need to inhibit multiple signaling pathways in myelofibrosis. For enzomenib, the findings clarified the mechanisms of acquired resistance after treatment and supported the investigation of sequential menin inhibitor therapy to improve treatment outcomes.